Fig. 6: Acute enhancement of EPS-induced contractile force by known muscle stimulating drugs. | Communications Biology

Fig. 6: Acute enhancement of EPS-induced contractile force by known muscle stimulating drugs.

From: Matrigel 3D bioprinting of contractile human skeletal muscle models recapitulating exercise and pharmacological responses

Fig. 6

a Effect of 10 mM caffeine (Caf) or solvent control (Con) on EPS-induced peak force and contraction duration (width50 and AUC [area under curve]) in 3D models from a 19-year-old donor differentiated for 20 days (n ≥ 8). Data are presented as means ± sem. Statistics: Unpaired t-test; ****p < 0.0001. b Time course of the effect of 20 µM troponin C activator Tirasemtiv on peak force production in a representative model from a 19-year-old donor differentiated for 18 days. c Relative effect of 20 µM Tirasemtiv (T) on peak force and contraction duration compared to before treatment (Con). Shown are means ± sem (n ≥ 10). Statistics: Unpaired t-test, ****p < 0.0001. d Time course of the effect of 0.2% DMSO solvent on peak force production in a representative model from a 19-year-old donor differentiated for 20 days. e Relative effect of 0.2% DMSO (D) on peak force and contraction duration compared to before treatment (Con). Shown are means ± sem (n ≥ 11). Statistics: Unpaired t-test, *p < 0.05. f Dose-response relation of the effect of Tirasemtiv on EPS-induced peak force in a representative model from a 19-year-old donor differentiated for 29 days. Shown are means ± sem (n ≥ 3). Statistics: One-way ANOVA, Dunnett’s multiple comparison test, **p < 0.01, ****p < 0.0001.

Back to article page